Trial Profile
Analysis of liver-related laboratory parameters in treatment-naive and peginterferon/ribavirin-experienced HCV genotype 1-infected patients with cirrhosis undergoing treatment with 3 direct-acting antiviral (3D) regimen of ABT-450/ritonavir/ombitasvir, dasabuvir, and ribavirin at week 12 or 24
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 28 Dec 2015 New trial record